Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

Uterine Fibroid Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT00232713 Org: User:
Start: 12/31/05 End: 12/31/05 Due: 12/31/06

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Phase: N/A Priority: Normal
NCT ID: NCT04885829 Org: User:
Start: 05/31/21 End: 05/04/23 Due: 05/04/24

The Ribavirin Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT00114712 Org: User:
Start: 01/31/04 End: 11/02/20 Due: 11/02/21

Study to Evaluate the AIO-001 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06170827 Org: User:
Start: 12/01/23 End: 07/15/24 Due: 07/15/25

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Phase: N/A Priority: Normal
NCT ID: NCT04993443 Org: User:
Start: 09/06/21 End: 03/09/23 Due: 03/09/24

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Phase: N/A Priority: Normal
NCT ID: NCT01803308 Org: User:
Start: 03/31/13 End: 08/31/14 Due: 08/31/15

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

Phase: N/A Priority: Normal
NCT ID: NCT05715736 Org: User:
Start: 03/08/23 End: 12/19/23 Due: 12/19/24

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05363839 Org: User:
Start: 05/06/22 End: 11/02/22 Due: 11/02/23

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

Phase: N/A Priority: Normal
NCT ID: NCT05088369 Org: User:
Start: 11/11/21 End: 12/19/22 Due: 12/19/23

Betaseron Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT00317564 Org: User:
Start: 04/30/06 End: 06/30/12 Due: 06/30/13

Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Phase: N/A Priority: Normal
NCT ID: NCT05053334 Org: User:
Start: 02/16/22 End: 01/10/24 Due: 01/10/25

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Phase: N/A Priority: Normal
NCT ID: NCT00404989 Org: User:
Start: 01/31/89 End: 01/31/99 Due: 01/31/00

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Phase: N/A Priority: Normal
NCT ID: NCT04879589 Org: User:
Start: 09/01/22 End: 04/20/23 Due: 04/20/24

First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

Phase: N/A Priority: Normal
NCT ID: NCT04925050 Org: User:
Start: 06/17/21 End: 01/23/24 Due: 01/23/25

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Phase: N/A Priority: Normal
NCT ID: NCT05896969 Org: User:
Start: 04/27/23 End: 02/23/24 Due: 02/23/25

Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05805618 Org: User:
Start: 07/01/24 End: 11/01/24 Due: 11/01/25

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04893512 Org: User:
Start: 06/30/21 End: 11/11/22 Due: 11/11/23

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03190824 Org: User:
Start: 12/22/16 End: 10/31/21 Due: 10/31/22

First-in-Human Study of SRT-015 in Healthy Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT04887038 Org: User:
Start: 05/03/21 End: 02/28/22 Due: 02/28/23

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06435039 Org: User:
Start: 06/21/24 End: 07/16/24 Due: 07/16/25

The Savella Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT01026077 Org: User:
Start: 11/30/09 End: 10/09/24 Due: 10/09/25